MedPath

Sidney Kimmel Cancer Center at Thomas Jefferson University

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Private
Employees
-
Market Cap
-
Website

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1
Withdrawn
Conditions
Stage IIIB Prostate Cancer
Stage IIIA Prostate Cancer
Stage IV Prostate Cancer
Stage III Prostate Cancer
Stage IIIC Prostate Cancer
Stage IVA Prostate Cancer
Stage IVB Prostate Cancer
Interventions
Procedure: Radical Prostatectomy
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Biological: Anti-PD-1 Monoclonal Antibody REGN2810
First Posted Date
2018-03-26
Last Posted Date
2025-04-29
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Registration Number
NCT03477864

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Early Phase 1
Completed
Conditions
Glioblastoma
Interventions
Radiation: Radiation Therapy
Device: NovoTTF-200A Device
Procedure: Tumor Treating Fields Therapy
First Posted Date
2018-03-26
Last Posted Date
2025-05-15
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
30
Registration Number
NCT03477110
Locations
πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Phase 2
Completed
Conditions
Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma
Stage IV Uveal Melanoma AJCC v7
Interventions
First Posted Date
2018-03-21
Last Posted Date
2025-04-24
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
14
Registration Number
NCT03472586
Locations
πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Refractory B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2018-03-21
Last Posted Date
2025-05-15
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
7
Registration Number
NCT03472573
Locations
πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

Phase 2
Active, not recruiting
Conditions
Melanoma (Skin)
Interventions
First Posted Date
2018-01-19
Last Posted Date
2025-04-24
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
26
Registration Number
NCT03405155
Locations
πŸ‡ΊπŸ‡Έ

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

πŸ‡ΊπŸ‡Έ

Columbia University, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 1 locations

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Phase 2
Withdrawn
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Drug: mFOLFIRNOX
First Posted Date
2017-12-15
Last Posted Date
2025-04-29
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Registration Number
NCT03374852

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2
Completed
Conditions
Non-Squamous Non-Small Cell Lung Carcinoma
Stage I Non-Small Cell Lung Cancer
Stage IIB Non-Small Cell Lung Carcinoma
Stage IA Non-Small Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer
Interventions
First Posted Date
2017-12-08
Last Posted Date
2023-04-03
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
14
Registration Number
NCT03366766
Locations
πŸ‡ΊπŸ‡Έ

Abington Hospital - Jefferson Health, Abington, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Phase 2
Completed
Conditions
Stage III Oral Cavity Squamous Cell Carcinoma
Stage IV Laryngeal Squamous Cell Carcinoma
Stage IV Oropharyngeal Squamous Cell Carcinoma
Stage IVA Hypopharyngeal Squamous Cell Carcinoma
Stage IVA Oral Cavity Squamous Cell Carcinoma
Stage IVB Laryngeal Squamous Cell Carcinoma
Stage IV Oral Cavity Squamous Cell Carcinoma
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Stage IVA Oropharyngeal Squamous Cell Carcinoma
Stage IVB Hypopharyngeal Squamous Cell Carcinoma
Interventions
First Posted Date
2017-11-17
Last Posted Date
2025-04-24
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
34
Registration Number
NCT03342911
Locations
πŸ‡ΊπŸ‡Έ

Abington- Jefferson Health, Abington, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Automated Device for Asthma Monitoring and Management in Monitoring Adults With Lung Cancer Undergoing Radiation Therapy

Completed
Conditions
Lung Carcinoma
Interventions
Device: Monitoring Device
First Posted Date
2017-11-13
Last Posted Date
2025-05-15
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
24
Registration Number
NCT03340714
Locations
πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Non-Hodgkin's Lymphoma
Plasma Cell Myeloma
Interventions
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis
First Posted Date
2017-10-23
Last Posted Date
2022-11-17
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
76
Registration Number
NCT03317899
Locations
πŸ‡ΊπŸ‡Έ

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Β© Copyright 2025. All Rights Reserved by MedPath